Israeli pharmaceutical firm Teva is negotiating what might be the largest purchase ever made in Israel, in a deal to acquire the US-based Barr Pharmaceuticals for a combination of cash and shares worth some $7.5 billion, a price approximately 35 to 45 percent higher than its current stock price.
Barr is also a major manufacturer of generic medications, as is Teva, but also produces other drugs as well. It currently has 70 products awaiting FDA approval and also is active in Europe, primarily Germany, Poland, Russia and Croatia.